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Background: The aim of this study was to explore the use of complementary and alternative
medicine (CAM) in cancer patients across a number of European countries.
Methods: A descriptive survey design was developed. Fourteen countries participated in the study
and data was collected through a descriptive questionnaire from 956 patients.
Results: Data suggest that CAM is popular among cancer patients with 35.9% using some form of
CAM (range among countries 14.8% to 73.1%). A heterogeneous group of 58 therapies were ident-
ified as being used. Herbal medicines and remedies were the most commonly used CAM therapies,
together with homeopathy, vitamins/minerals, medicinal teas, spiritual therapies and relaxation tech-
niques. Herbal medicine use tripled from use before diagnosis to use since diagnosis with cancer.
Multivariate analysis suggested that the profile of the CAM user was that of younger people, female
and with higher educational level. The source of information was mainly from friends/family and
the media, while physicians and nurses played a small part in providing CAM-related information.
The majority used CAM to increase the body’s ability to fight cancer or improve physical and
emotional well-being, and many seemed to have benefited from using CAM (even though the
benefits were not necessarily related to the initial reason for using CAM). Some 4.4% of patients,
however, reported side-effects, mostly transient.
Conclusions: It is imperative that health professionals explore the use of CAM with their cancer
patients, educate them about potentially beneficial therapies in light of the limited available evidence
of effectiveness, and work towards an integrated model of health-care provision.
Key words: alternative medicine, complementary medicine, Europe, herbs, homeopathy, spiritual
healing, vitamins
Introduction
Complementary and alternative medicine (CAM) has been
defined as ‘any diagnosis, treatment or prevention that comp-
lements mainstream medicine by contributing to a common
whole, by satisfying a demand not met by orthodoxy or by
diversifying the conceptual framework of medicine’ [1, 2].
The use of CAM has increased steadily over the past 15 years
or so, and undoubtedly it has gained medical, economic and
sociological importance [3]. However, little is known about
the use of CAM in cancer patients specifically. This is
especially true in the context of Europe, as the bulk of the
literature comes from the USA.
A survey conducted in 33 countries, yielding a meagre 83
responses mainly from oncologists, indicated the existence of a
large and heterogeneous group of CAM therapies or remedies
used to treat cancer in both developed and developing countries
[4]. A literature review suggested that the use of CAM among
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cancer patients is common, with a prevalence rate across
studies of 31.4% (range 7% to 64%) [3]. The latter review
included 26 surveys from 13 countries carried out from 1977 to
January 1998. However, more recent studies suggest that the
use of CAM is considerably higher, with some studies report-
ing rates of 70.2% in a sample of 356 colon, breast and prostate
cancer patients [5], and 83.3% in an outpatient sample of 453
patients [6]. Depending on the instrument used to collect the
data, the particular population under study, the sample size and
the CAM definition used, studies report rates from 37% to 87%
[7–11]. In paediatric patients rates are equally high, ranging
from 32.7% in the UK [12] to 84% in the USA [13].
The most popular therapies seem to be dietary treatments,
herbalism, homeopathy, hypnotherapy and imagery/visualisa-
tion [2]. Spiritual therapies, prayer as a therapy, massage,
shark cartilage, green tea, support groups and non-traditional
diets are also commonly reported in the literature [6, 9, 11,
14, 15]. Improvements in physical and psychosocial well-
being and increasing hope are the main reasons cancer patients
turn to CAM [11], although dissatisfaction with some aspects
of conventional health care, poor doctor–patient relationship,
accessibility, perceived effectiveness and desperation may also
be key motivating factors [16].
CAM includes a wide range of therapies. The National Cen-
ter for Complementary and Alternative Medicine in the USA
classifies CAM therapies into five categories [17]:
(i) alternative medical systems, such as traditional Chinese
medicine or Ayurveda;
(ii) mind–body interventions, such as meditation, prayer,
healing or support groups;
(iii) biologically based therapies, such as herbs, dietary sup-
plements or vitamins;
(iv) manipulation and body-based methods, such as massage,
chiropractic or osteopathy; and
(v) energy therapies (i.e. biofield therapies such as Qi Gong
and Reiki or bioelectromagnetic-based therapies such as mag-
netic fields).
The aim of the present study was to assess the use of
complementary and alternative therapies across a number of
European countries, using the same measurement tool and
same definition of CAM.
Patients and methods
Patients and settings
A cross-sectional descriptive survey design was used to collect data
through a questionnaire about CAM therapies. Eighteen National Oncol-
ogy Nursing Societies, all members of the European Oncology Nursing
Society, were approached for possible collaboration. Of the 18 societies,
15 agreed to participate, although one withdrew later on. A key person
from each society was selected, based on interest and/or experience in
CAM. Each person had to translate the questionnaire into their own coun-
try’s language, apply to the ethics committee in each hospital involved in
the study and collect the data. In certain countries the questionnaire had
to be altered slightly, as some of the 25 ethics committees where the
study was assessed requested changes (i.e. in Switzerland collecting data
on income levels was not recommended to be included as a variable).
Also, in most cases, researchers did not have access to patients’ medical
records. Data collected from each country were returned to one of the
investigators and then data were coded for analysis. On many occasions,
data had to be translated back to English, especially qualitative comments
patients made on the questionnaire.
Data were collected in the outpatient clinics of a number of hospitals
over several random days. On the selected days, all patients attending a
given clinic were approached for possible inclusion in the study. In most
countries data were collected from more than one hospital, and in five
countries there were hospitals included from large cities as well as rural
units. Both metastatic and non-metastatic cancer patients were included
from cancer centres, oncology units of general hospitals, day units, radio-
therapy units and hospices.
All participating patients received information about the study and in
most countries those volunteering to participate signed a consent form.
However, in a small number of countries (i.e. England) a written consent
form was not necessary, and completing the questionnaire implied that
patients volunteered for the study. Patients were included if they met the
following inclusion criteria: they were adult patients of either gender with
a diagnosis of cancer; aware of their diagnosis; able to understand the
questions; free from any condition that would make completing the ques-
tionnaire inappropriate or overburdening for the patients; and they were
willing to participate in the study.
In several countries, especially the Mediterranean and Eastern European
ones, data collection proved to be difficult, as a substantial number of
patients did not meet one of the inclusion criteria, namely that of being
aware of their diagnosis.
Procedures
The questionnaire was anonymous and was handed out to the patients
after they received information about the study, agreed to participate and
signed the consent form. Patients completed the questionnaire while they
were waiting at the outpatient clinic to be seen by their physician or
during therapy. On completion, patients either put the questionnaire in a
box or handed it to the local researcher. Owing to the multinational nature
of the study, it was not possible to assess the number or characteristics of
those declining to participate.
The questionnaire
The questionnaire used was based on the one developed by Swisher et al.
[11]. However, the questionnaire was modified for the purposes of the pre-
sent study and some new items were added (for example, personal spend-
ing on CAM and frequency of CAM use) and some others were modified
to reflect European culture (for example, items on ethnic background and
financial status). There were 27 items in total. These included demo-
graphic data (age, gender, occupation, education, household income, mari-
tal status, number of people living in the household and ethnicity), clinical
data (site of primary cancer, standard treatments received previously and
current standard treatment) and questions about CAM use.
If patients reported no past or current use of CAM after completing the
sociodemographic and clinical section of the questionnaire, they were
asked to choose an answer from a list of possible reasons for not using
CAM. After that, patients were thanked for their contribution and asked to
stop completing the questionnaire at that stage. If patients reported past or
current use of CAM, they were asked to continue. The rest of the ques-
tions asked were:
. Which CAM therapy patients used before the diagnosis of cancer, since
the diagnosis of cancer or currently. ‘Since diagnosis’ was defined as
any time from the moment a diagnosis of cancer was made until the
present time, and ‘currently’ was defined as actually using a CAM
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therapy at the present time. This was done from a list of 26 possible
therapies, with space to add other therapies if appropriate. Examples of
therapies listed were spiritual therapies, herbs, animal extracts, osteopa-
thy, chiropractic, mega-vitamins, aromatherapy, Qi Gong, acupuncture
and others.
. Types of CAM practitioners consulted before the diagnosis of cancer,
since the diagnosis of cancer or currently.
. Method of use of the reported therapy (i.e. by mouth, injection or
enema).
. Frequency of use of reported therapy.
. Reasons for using CAM therapies.
. Benefits experienced by the use of CAM.
. Ill effects or side-effects from using the reported CAM therapy.
. Expenditure on CAM.
. Satisfaction and perceived effectiveness (on a 0–7 scale with higher
scores indicating higher levels of satisfaction or perceived effective-
ness).
. Sources of information about CAM therapies.
Data analysis
Data were analysed using the Statistical Package for Social Sciences
(SPSS) programme. Descriptive statistics were calculated with all vari-
ables to summarise the data. Differences in sociodemographic character-
istics between CAM users and non-users were assessed using the x2-test.
Spearman correlation coefficients were also calculated between CAM use
and other variables of interest. Finally, multivariate analysis was used to
assess which variables predicted CAM use.
Results
Participating countries
Fourteen countries completed the study, providing a total of
956 patient-completed questionnaires for evaluation. Table 1
shows the countries and the number of questionnaires returned
from each country.
Sociodemographic and clinical characteristics
of the sample
A total of 591 (61.8%) female and 365 (38.2%) male patients
participated in the study. Their mean age was 55.68 years
[range 17–91; standard deviation (SD) 12.78]. The most fre-
quent diagnosis included breast (n = 282; 30.8%), colorectal
(n = 148; 16.1%) and lung (n = 111, 12.1%) cancer. Most
participants (n = 703; 74%) were married. The vast majority
(98.5%) were of white ethnic background. Most were earning
<20 000 Euros annually (72.5%). Most (n = 767; 82%) were
currently receiving standard treatment. More details are shown
in Table 2.
Use of CAM
Past or current CAM use was reported by 35.9% (n = 342) of
the total patient population. CAM use ranged from 14.8% to
73.1% (see Table 1). Use of CAM ranged from 1 month up to
18 years in some cases (mean 27 months). In most countries,
around one-third of patients were using some form of CAM,
with only Switzerland, the Czech Republic and Italy showing
high levels of CAM use and Greece showing very low levels
of use (Table 1). It was interesting to see that CAM use was
lower before the diagnosis of cancer, increased by at least
30% since diagnosis and current use stabilised at a little higher
(8%) than the CAM use before diagnosis. Thirty-eight differ-
ent therapies had been used before the diagnosis, 46 since
diagnosis (10 were new types never used before by the
patients) and 39 types of therapies were currently used. In
total, 58 different CAM therapies were reported. Table 3
shows the frequency of use of different CAM therapies before
diagnosis, since diagnosis and currently.
There were significant differences in CAM use among the
different cancer diagnostic groups of the sample. The highest
prevalence rate of CAM use was in pancreatic, liver, bone/
spinal and brain cancer patients, followed by breast, stomach,
gynaecological and genitourinary cancers. The lowest rates of
CAM use were observed in lung and head and neck cancer
patients (Table 4).
Patients who paid for CAM privately were also asked to
report how much, on average, they spent on such therapies or
remedies. Patients were spending an average of e123/month,
and the maximum reported amount was e4140/month. How-
ever, less than half the patients using CAM actually paid for
such therapies or remedies (n = 188/342), as most of the reme-
dies used were easily available without a charge (i.e. by col-
lecting herbs themselves or by relatives collecting herbs from
the mountain or given by friends).
The five most frequently used broad categories of therapies
were similar across most countries. Herbs were the most com-
monly used CAM therapy in 13 out of 14 countries and they
were the number one CAM therapy in nine countries (Turkey,
Israel, Serbia, Czech Republic, Denmark, Italy, Switzerland,
Table 1. Participating countries, number of patients per country
(in descending order) and frequency of CAM use
Country n % CAM use
[n (%)]
CAM non-use
[n (%)]
Spain 115 12 34 (29.8) 81 (70.2)
Israel 111 11.6 36 (32.4) 75 (67.6)
Turkey 100 10.5 37 (37) 63 (63)
Scotland 93 9.7 27 (29) 66 (71)
Greece 81 8.5 12 (14.8) 69 (85.2)
Switzerland 72 7.5 35 (48.6) 37 (51.4)
Sweden 59 6.2 18 (30.5) 41 (69.5)
Italy 52 5.4 38 (73.1) 14 (26.9)
Czech Republic 51 5.3 30 (58.8) 21 (39.2)
Serbia 50 5.2 16 (32) 34 (68)
Denmark 50 5.2 18 (36) 32 (64)
Belgium 45 4.7 18 (40) 27 (60)
Iceland 43 4.5 13 (30.2) 30 (69.8)
England 34 3.6 10 (29.4) 24 (70.6)
CAM, complementary and alternative medicine.
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Spain and Greece) and in the top five in all countries but
Sweden. Homeopathy was the most commonly used CAM
therapy in Belgium and in the top five in six other countries
(Turkey, Czech Republic, Sweden, Italy, Spain and Greece).
Medicinal teas were also in the list of the five most frequently
used CAM therapies (seven countries), as were vitamins/mine-
rals (nine countries). Most herbs were specific to each country
(i.e. mistletoe in Switzerland, olive leaf paste in Greece, nettle
leaves/tea in Turkey, aloe vera in Serbia and Spain or Ovosan
in the Czech Republic). Israel, Denmark, Italy, Spain,
Greece and Iceland featured strongly in relation to spiritual
therapies.
The types of herbs or biological ingestibles used by partici-
pants were also assessed, as we asked participants to write
down the names of herbs/remedies used. Herbs and other bio-
logical ingestibles used included green tea, essiac tincture,
Chinese herbs, sage tablets, Echinacea, cod liver oil, fresh
juice and vegetables, vitamin E, glucosamine, chamomile,
peppermint, selenium, mistletoe/Iscador, yeast extract, multi-
vitamins, Ayurveda herbs, vitamin C, soya drinks, dry thyme,
dry nettle, nettle tea, nettle or nettle seeds mixed with honey,
ginseng, mulberry molasses, shark cartilage, fish oil, gingko
biloba, milk thistle, minerals (i.e. Zn, Ca, Mg), aloe vera
(orally and externally used), papaya tea, beet and carrot juice,
paste from olive leaves, a mixture of aloe–honey–rhaki and
wine, and angelica herb. Most herbs were used to treat the
cancer, although no participant specified for which specific
condition they were using which method.
Table 2. Sociodemographic and clinical characteristics of the samplea
n %
Gender
Female 591 61.8
Male 365 38.2
Education level
Illiterate 3 0.3
Primary education 290 30.6
Secondary education (high school) 375 39.5
College/University education 164 17.3
Postgraduate education 72 7.6
Professional/technical schools 44 4.6
Occupation
Retired 254 27.9
Educational profession 45 4.9
Managerial profession 69 7.6
Housewife 126 13.8
Manual worker 257 28.2
Clerical staff 65 7.1
Health professional 46 5
Engineering 25 2.7
Unemployed 24 2.6
Marital status
Single 98 10.3
Married 703 74
Divorced/separated/widowed 70/10/69 7.4/1.1/7.3
Ethnicity
Caucasian 932 98.5
Black 5 0.5
Asian 10 1
Annual income (in e)
<10 000 324 44.9
10 001–20 000 199 27.6
20 001–30 000 92 12.7
30 001–40 000 46 6.4
>40 000 61 8.4
Primary cancer
Breast cancer 282 30.8
Colorectal cancer 148 16.1
Lung cancer 111 12.1
Head and neck cancer 75 8.2
Gynaecological cancers 72 7.9
Haematological cancers 69 7.6
Genitourinary cancers 40 4.4
Stomach cancer 31 3.4
Prostate cancer 30 3.3
Bone/spine cancers 22 2.4
Pancreatic cancer 16 1.7
Table 2. (Continued)
n %
Liver cancer 9 1
Malignant melanoma 8 0.9
Brain tumors 4 0.4
Past treatment received (n = 713)
Surgery alone 120 16.8
Chemotherapy 106 14.9
Radiotherapy 41 5.8
Surgery and chemotherapy 155 21.7
Chemotherapy and radiotherapy 68 9.5
Surgery, chemotherapy and radiation 159 22.3
Other combinations 16 8.8
Currently receiving treatment (n = 767; 82.1%)
Surgery alone 8 1.1
Chemotherapy 597 78.8
Radiotherapy 35 4.6
Surgery and chemotherapy 20 2.6
Chemotherapy and radiotherapy 43 5.7
Surgery, chemotherapy and radiation 16 2.1
Other combinations 39 5.2
aNot all frequencies add up to 956 subjects, as there were missing data.
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Patients tended to be satisfied with the use of CAM and
they also felt the particular therapy used was effective. The
mean satisfaction score was 5.27 (SD 1.52), where a score of
7 indicated the most satisfied. Similarly, the mean score for
perceived effectiveness was 5.04 (SD 1.52).
Frequency of use
Thirty-three different types of CAM practitioners were con-
sulted. Seven patients (6.3%) received CAM therapy through
their general practitioner/family doctor. Most patients who
were visiting a CAM practitioner (n = 111) did so less than
once a month (34.2%), once a week (24.3%) or once a month
(22.5%). Some 8.1% of patients visited a CAM practitioner
once a month and 8.1% of patients visited a CAM practitioner
2–3 times a week. Furthermore, 2.7% visited a practitioner
almost daily.
Reasons for using CAM and perceived benefits
from its use
Most patients were using CAM as they wanted to increase
their body’s ability to fight the disease (50.7%), improve
physical well-being (40.6%) or improve emotional well-being
(35.2%) (Table 5). However, there were some differences in
the reasons for using CAM therapies and the experienced
benefit from them. In more detail, although the primary reason
stated for using CAM was to increase the ability to fight
the cancer, only 22.4% found CAM of benefit (P <0.001).
Additionally, it is interesting to note that 42.5% found CAM
to be helpful in improving emotional well-being, although this
was only identified as a reason for use in 35.3% of the sample
(P <0.01). Only 31 patients (3.2%) found the CAM thera-
py/therapies they used were not of benefit at all.
Sources of information about CAM
Patients were asked to note where they had learnt about the
CAM therapy they used/were using. Friends were the most
common source of information (56.5%), followed by family
(29.1%) and the media (28.4%). Other sources of information
Table 3. Complementary and alternative medicine therapies used before
the diagnosis of cancer, since diagnosis and currently
Before
diagnosis
Since
diagnosis
Currently
n % n % n %
Alternative medical systems:
homeopathy
59 6.2 58 6.1 36 3.8
Alternative medical systems:
acupuncture
37 3.9 29 3 18 1.9
Alternative medical systems:
Ayurveda
2 0.2 5 0.5 4 0.4
Alternative medical systems:
naturopathy
5 0.5 7 0.7 4 0.4
Biologically based therapies/
alternative medical systems:
herbs
57 5.9 149 15.2 118 12.1
Biologically based therapies:
medicinal teas
25 2.6 51 5.3 43 4.5
Biologically based therapies:
vitamins/minerals
26 2.7 50 5.2 49 5.1
Biologically based therapies:
other dietary supplements
15 1.6 34 3.5 19 1.9
Biologically based therapies:
other
20 2.1 18 1.8 13 1.3
Mind–body interventions:
spiritual therapies and healing
31 3.2 52 5.4 30 3.1
Mind–body interventions:
relaxation therapy
18 1.9 44 4.6 35 3.7
Mind–body interventions:
visualisation
10 1 28 2.9 22 2.3
Mind–body interventions: other 30 3.1 57 5.9 40 4.2
Energy therapies 31 3.2 20 2.1 14 1.5
Manipulative and body-based
methods: massage
43 4.5 37 3.9 22 2.3
Other manipulative and
body-based methods
55 5.7 34 3.6 18 1.9
Alternative medical systems: homeopathy, Chinese herbal medicine and
acupuncture, Ayurveda, naturopathy.
Biologically based therapies: herbs, dietary supplements (animal
extracts, coenzyme Q10), vitamins/minerals, medicinal teas, diets
(juicing, macrobiotic diet, fasting therapy), aromatherapy, oxygen
therapy, Bach flowers, cannabis smoking, bioresonance therapy,
Iscador injections.
Mind–body interventions: spiritual therapies and healing, relaxation,
visualisation, hypnotherapy, psychic therapies, curandero, support
groups, yoga, art therapy, autogenic training, Alexander technique,
anthroposophic medicine, bio-orgonomy.
Energy therapies: Tai Chi, Qi Gong, electromagnetic therapy, Reiki,
Shiatsu, energy healing.
Manipulative and body-based methods: massage, chiropractic,
osteopathy, drainage therapy/lymphatic massage, reflexology, zone
therapy.
Numbers and words shown in bold represent most frequent single CAM
therapies used.
Table 4. Frequency of CAM use by cancer diagnostic group
(in descending order)
Diagnostic group % of CAM use
Pancreatic cancer 56.3
Liver cancer 55.6
Bone/spinal cancer 54.5
Brain cancer 50
Breast cancer 44.7
Stomach cancer 41.9
Gynaecological cancers 40.3
Genitourinary cancers 40
Colorectal cancer 32.7
Prostate cancer 30
Haematological cancers 26.5
Melanoma 25
Lung cancer 23.6
Head and neck cancer 22.7
CAM, complementary and alternative medicine.
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included patient’s physician (18.6%), CAM practitioners
(12.9%), the Internet (9.3%), their nurses (3%), religious
groups (2.4%), personal knowledge (1.8%) and other patients
who used CAM (1.5%).
Side-effects
Fourteen patients (4.4%) reported side-effects from the CAM
therapy they had used. Most seemed to be transient
side-effects and they were all related to ingesting herbs or
minerals. Responses were obtained from seven countries.
These side-effects included stomach aches (one incident with
thyme and nettle tea, one with vitamin C, and one with aloe);
gastric upset and nausea from using nettle tea (one report);
itching [one incident with nettle leaves, one with selenium
tablets and one with Iscador (mistletoe)]; headaches and
migraine (one incident, unspecified herbs); diarrhoea (one
incident, unspecified herbs); and poor renal status/accumula-
tion of body acid (one incident with vitamin C).
Multivariate analysis
Spearman correlation coefficients showed that the use of
CAM was associated with younger age (rs = 0.18; P <0.001),
female gender (rs = 0.14; P <0.001), higher education level
(rs = 0.15; P <0.001), higher annual income (rs = 0.08;
P = 0.025) and previous standard treatment (rs = 0.12;
P <0.001), although these correlations were weak. These were
also the variables that differed significantly between the users
and non-users of CAM (x2-tests). Additionally, occupation
was also different between users and non-users (P = 0.008). A
multivariate model of sociodemographic and clinical charac-
teristics showed that three variables were the strongest predic-
tors of CAM use: younger age, female gender and higher
educational level (P <0.001). However, the model could only
explain 26% of the variance in the use of CAM.
Why patients do not use CAM
Patients who were not using CAM were asked to note why
they did not do so. The majority (n = 236; 43.4%) reported
that they were happy with the conventional treatment they
received/were receiving. Also, 34.7% (n = 189) reported that
they never thought of CAM and 15.1% (n = 82) that they did
not believe in CAM. Other reasons included discouragement
from family (n = 12; 2.2%), lack of information about CAM
(n = 11; 2%), and inability to pay for CAM (n = 9; 1.7%). Five
patients (0.9%) noted that they were interested in CAM but
they had not decided to use any as yet.
Discussion
The current study constitutes one of the largest surveys to date
on the use of CAM in cancer patients, and is the only
European-wide survey available. As such, it provides initial
evidence of the extent of the use of CAM therapies, types,
reasons behind use or non-use, perceived benefits, expendi-
ture, and commonly observed side-effects. It has shown that
although Europe consists of a diverse cultural population,
CAM use has more similarities than differences across
Europe. It is shown that the most popular CAM therapy in
cancer patients is the use of medicinal herbs or remedies,
although the variety of herbs used differed by country.
More than one-third (35.9%) of the cancer patients reported
using some form of CAM, with little variation across
countries. This is an increase of the average mean CAM use
from that reported in a review of 29 studies covering 20 years
[3]. Similar to the study by Ernst and Cassileth [3], there was
great variability in the use of CAM, and this may partly be the
result of the patient’s understanding of what CAM is. A stan-
dardised protocol was used in the current study to minimise
such biases, and the definition used was as broad and inclusive
as possible. The variability probably also reflects adjunctive
use of CAM, as the sample was derived exclusively from
health-care settings.
Nevertheless, CAM use is considerably lower in the present
study than surveys reporting results from US samples. US
studies demonstrate a much higher use of CAM, which is
often well above 40% [6, 8, 9, 15]. This could indicate that
the concept of a more holistic approach to medicine or the use
of an integrated model of health-care provision is lagging in
Europe compared with the USA. North Americans may also
be using CAM more frequently due to the wider influence that
ethnic groups may have had on Western (scientific) medical
philosophy, and the realisation that some of the CAM thera-
pies may be beneficial to patients and possibly cost-effective.
Furthermore, Kessler et al. [18] also suggest that the trend in
the use of CAM in the USA may be a result of a secular trend
that began about half a century ago, which nevertheless high-
lights the increasing patient demand for such therapies. How-
ever, the limited available data on the effectiveness of various
CAM therapies also highlights the necessity to be selective
and careful (but open minded) about CAM therapies.
Table 5. Reasons for using CAM and perceived benefits
Reasons for using CAM Benefits
experienced
n % n %
To directly fight the disease with
alternative therapy/decrease tumor
55 16.4 13 3.9*
To increase the body’s ability to
fight the cancer
170 50.7 75 22.4*
To improve physical well-being 136 40.6 152 45.4
To improve emotional well-being,
provide hope and increase
optimism
118 35.2 143 42.8
To counteract ill effects from the
tumor or medical treatments
83 24.8 76 22.6
‘Might help, can’t hurt’ 77 23.1 – –
Desire to do everything possible to
fight the disease
76 22.6 – –
Requested by physician 3 0.9 – –
CAM, complementary and alternative medicine.
*P <0.001.
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The country with the highest CAM use was Italy, but as the
source of data was from a palliative care unit these results
may not be accurate. An observation of the study was that par-
ticipants from palliative care facilities tended to use CAM
more often, but the mixed settings in most of the countries
participating in the study did not allow us to validate this
observation. Furthermore, another observation was that CAM
use was higher in cities, but when samples from rural hospitals
within the same country were added, it decreased the overall
number of users. This was especially true in Greece and
Spain, where such data were available. Hence, use of CAM
therapies may also be related to the availability of such thera-
pies in a given geographical setting. The lowest frequency of
CAM use was observed in Greece, and this may reflect the
lack of availability of many CAM therapies, high compliance
with conventional medical treatments, cultural norms or con-
cealing use of CAM in order to avoid any conflict of opinion
with the health-care team. Indeed, before completing the study
questionnaire, many participants from a number of countries
in the study did mention that they did not want their health-
care team to know about their use of CAM.
A large number (n = 58) of heterogeneous CAM therapies
was reported. Confirming earlier reports, herbals and medi-
cinal teas, vitamins and minerals, spiritual therapies, homeo-
pathy, and relaxation techniques were the CAM therapies used
more often in this current sample [7–11]. These did not differ
substantially among all the countries involved in the study.
Perhaps reflecting cultural preferences, availability and
national legislation from country to country, differences were
observed in the less frequently used CAM therapies. Based on
the CAM classification by the National Center for Comp-
lementary and Alternative Medicine [17], most patients were
using biologically based therapies. This highlights the attrac-
tiveness for patients of ‘natural’ therapies and remedies, but
also suggests that patients may be at risk of side-effects or, as
most patients were currently receiving treatment, interactions
with conventional medicines. Several good reviews of such
side-effects have been presented in the literature (e.g.
Niggemann and Gruber [19]). The role of CAM in affecting
(positively or negatively) the outcomes of pharmaceutical
clinical trials in cancer care is also an issue that needs atten-
tion, as many patients involved in trials will also be using
CAM therapies.
Patients typically used more than one CAM therapy
together. This fact alone makes research into the effectiveness
of CAM using traditional trial designs complicated. It was
also interesting to see that only a small number of patients
used support groups. This was 0.3% before the diagnosis of
cancer (reflecting presence of other chronic conditions),
increasing to 1.8% at some point since the diagnosis of cancer
and only 1.4% using support groups currently. This is con-
siderably lower than rates reported in past psychosocial litera-
ture [20, 21], perhaps highlighting the lack of availability of
support groups in many countries in Europe. However, past
research on support groups comes mainly from America, with
data commonly collected from breast cancer patients and
specialist clinics, so the higher rates reported may not be gen-
eralisable to all cancer patients. Further, as can be seen in
Table 3, the overall use of energy therapies (often used for
‘wellness’ rather than specific illnesses) and manipulative
methods were decreased after the diagnosis of cancer (with
the exception of electromagnetic therapy and massage).
Herbal medicines were by far the most commonly used
therapy, escalating in use from 5.3% before the diagnosis of
cancer to 13.9% (an almost three-fold increase) after the diag-
nosis of cancer. A wide range of herbs were recorded as being
used. These differed from country to country, probably based
on specific ethnopharmacological information and tradition, as
well as availability. For example, among others, Turkey
reported most commonly the use of nettle leaves/teas, as well
as thyme, often mixed with other compounds; Scotland
reported more often the use of green tea; Switzerland used
mistletoe more often (a particularly popular herb in German-
speaking countries); the Czech Republic used Ovosan (a
locally produced tablet combining a number of herbs),
selenium, ginseng, gingko biloba and Echinacea; Sweden
reported the use of blood salts and ginseng; Serbia and Spain
reported more often the use of aloe vera; Greece reported the
use of a paste made from olive leaves; Iceland reported the
use of lupine extracts (angelica) and green tea; and Israel and
England reported the use of multivitamins.
It was interesting to see the wide variation in the prevalence
rates of CAM use among different diagnostic groups. Despite
suggestions from the literature that breast cancer patients are
more likely to use CAM compared with other cancer patients
[22], the present study showed that pancreatic, liver, bone and
brain cancer patients used CAM therapies significantly more
often than any other cancer patient group. All four of these
diagnostic categories are characterised by poor prognosis and
a rapid physical decline, often with metastasis present, and
such patients may have little hope from conventional treat-
ments, turning to CAM as an additional intervention to
improve their lives. The role of CAM not only in increasing
hope and optimism, but also in improving quality of life and
managing symptoms, especially in terminal illness, may be
important, but relevant data in cancer patients is almost non-
existent to date. However, some of the results in this subgroup
analysis should be viewed with caution, as only a small num-
ber of patients participated from some of the diagnostic cat-
egories. Also, a longitudinal design could have given more
accurate information about variation of CAM use along the
patient’s disease experience.
Patients seem to be satisfied with the use of CAM, even if
they do not see any obvious benefit from it. A wide range of
reasons contribute to the use of CAM, and perhaps the concept
of ‘hope’ is fundamental in each one of these reasons. More
than two-thirds of the patients used CAM therapies to directly
fight the cancer or to increase the body’s ability to fight can-
cer, but eventually they found little benefit for this. However,
those who used CAM to improve physical and emotional
well-being seemed to have benefited from CAM. These find-
ings coincide with findings from the USA [11]. It is interesting
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to see that <1% of the patients used CAM following the rec-
ommendation of their physician, perhaps reflecting the disap-
proval of CAM therapies by the medical community or the
lack of information to the medical community about available
and effective CAM therapies. Examples of such information
include the consistently positive results with acupuncture in
the management of chemotherapy-related nausea and vomiting
[23]; the positive effects of self-hypnosis, massage or acu-
puncture in pain relief in cancer patients [24]; the relief of
dyspnoea with acupuncture, acupressure or relaxation/breath-
ing techniques [24]; the positive short-term benefits of mas-
sage and aromatherapy massage on psychological well-being
[25]; and the promising results from the use of mistletoe in
relation to survival, management of side-effects or quality of
life in cancer patients [26]. Also, <4% used CAM to directly
fight the disease (i.e. as an alternative cancer treatment) and
the overwhelming majority used CAM to complement their
cancer treatment or help them cope with the treatment and/or
its side-effects. As many of the therapies used are ‘comp-
lementary’ in nature (such as aromatherapy, massage, relax-
ation, reflexology and others), we may not need to prove their
effectiveness before using them, as patients are demanding
such therapies, they are low-risk therapies and patients feel
good after their use. Such therapies may have a great role to
play, especially in the palliative care setting, where the goal is
not cure but rather improvement in quality of life. Patient sat-
isfaction can be an appropriate end point outcome for evalu-
ation rather than clinical outcome studies in this setting.
A wide variety of sources of information were used before
patients selected a given therapy. Friends and family or word
of mouth seemed to be the most important sources of infor-
mation. This may be problematic, as what is effective for one
patient may not be for another, even with the same symptoms.
Also, the media was shown to be a common source of infor-
mation, and this may again be problematic, as the media often
sensationalises patient stories without balancing the infor-
mation presented. The role of physicians as sources of infor-
mation was quite low, with only 18.6% actually providing
information to patients. This number is even lower among
nurses: only 3% of nurses were identified as the main source
of information for patients. Health professionals need to be
able to provide information about CAM to their patients,
although the knowledge deficit is acknowledged. The Internet
is another commonly used source of information, but the
commercial nature of many relevant websites (especially in
relation to herbs) and the lack of quality assessment of the
information posted on the web may be sources of misinforma-
tion [27].
Findings should be evaluated in light of the limitations of
the study. The European-wide nature of the study was difficult
to conduct, and it was difficult to maintain consistency,
because of its international breadth and specific requests from
various ethics committees or hospital boards. As we did not
have access to medical records, we could not ascertain
whether there was metastatic disease or not and other, more
sensitive clinical data. There is also an overlap between the
users of CAM ‘since diagnosis’ and ‘currently’. Based on the
selected design of the study, made simple and anonymous to
fulfil recruitment criteria in all the countries involved, it was
difficult to track patients who refused participation (albeit
recruitment rates of >90% were achieved in the majority of
the cases, based on individual researchers’ comments).
Finally, as the samples were taken from different settings, pat-
terns of use may reflect different rates because of the setting
rather than the countries concerned.
Irrespective of what health professionals believe about
CAM and how dismissive of CAM they may be, it is evident
that patients are using, and will continue to use, CAM thera-
pies. Hence, from a professional point of view, health-care
staff need to be aware of such use of CAM and to be able to
educate patients appropriately. This will probably necessitate
the rethinking of the provision of medical and health-care edu-
cation, broaden our understanding of the concept of medicine
and help us work towards integrating into mainstream health-
care services those CAM therapies for which evidence of
effectiveness exists. This debate has already been discussed
elsewhere (i.e. Owen et al. [28]). At the same time, there will
be a need for considerable increase in the funding for CAM
research. Currently only the National Center for Complemen-
tary and Alternative Medicine, National Institutes of Health in
the USA provides substantial funds for such research, and
other organisations and countries would need to follow their
example. In the UK, research funding for CAM has increased
over the years but, until recently, this was still only  0.31%
of all funding available for medical research, suggesting that
funding is low [29]. The need to increase the evidence base of
CAM therapies, using methodologies that are appropriate and
sensitive to CAM, cannot be overemphasised. This is also
important from an economic point of view, as the use of
CAM is a multibillion Euro business, and as shown in this
study, some patients pay large sums out of their pockets to
receive such interventions. In the USA, where such data are
available, the use of CAM is conservatively estimated to cost
patients US$27 billion (for the year 1997) [30]. In Europe it is
the second biggest growth industry [31]. Finally, appropriate
legislation and regulation of CAM therapies in Europe is also
necessary. While many countries have developed their own
regulation and legislation [32], there are wide variations in
such laws across Europe. Since it would appear that CAM is
here to stay, the European Community needs to consider
broader policies, common laws and a rationalisation of the
available legislation.
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